| Drug Name |
Topotecan |
| Drug ID |
BADD_D02248 |
| Description |
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. |
| Indications and Usage |
For the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01CE01 |
| DrugBank ID |
DB01030
|
| KEGG ID |
D08618
|
| MeSH ID |
D019772
|
| PubChem ID |
60700
|
| TTD Drug ID |
D02PMO
|
| NDC Product Code |
16729-243; 0409-0302; 0703-4714; 0078-0672; 0078-0673 |
| UNII |
7M7YKX2N15
|
| Synonyms |
Topotecan | 9-Dimethylaminomethyl-10-hydroxycamptothecin | 9 Dimethylaminomethyl 10 hydroxycamptothecin | Topotecan Hydrochloride | Hydrochloride, Topotecan | Nogitecan Hydrochloride | Hydrochloride, Nogitecan | Topotecan Monohydrochloride, (S)-Isomer | SK&F-104864-A | SK&F 104864 A | SK&F104864A | SKF-104864-A | SKF 104864 A | SKF104864A | Hycamtin | NSC-609699 | NSC 609699 | NSC609699 | Hycamtamine |
